HF
EBS icon

Hoxton Financial’s Emergent Biosolutions EBS Stock Holding History

Hoxton Financial’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-117
Closed -$3K – 405
2013
Q4 		$3K Buy
117
+41
+54% +$855 ﹤0.01% 587
2013
Q3 		$1K Buy
+76
New +$1.36K ﹤0.01% 433

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hoxton Financial's EBS Position: Q1 2014 in Review

Hoxton Financial sold out of Emergent Biosolutions (EBS) in Q1 2014, closing a stake of 117 shares — an estimated $3K sold.

Hoxton Financial first reported a position in EBS in Q3 2013 and held it in 2 quarters. The position peaked at $3K in Q4 2013. 168 funds tracked by Wall St. Rank hold EBS as of Q1 2014.

  • Hoxton Financial reported no remaining Emergent Biosolutions position as of Q1 2014 after selling out during the quarter.
  • Hoxton Financial sold 117 Emergent Biosolutions shares in Q1 2014, an estimated $3K.
  • Hoxton Financial first reported a position in Emergent Biosolutions in Q3 2013 and held it in 2 quarters.
  • Hoxton Financial's Emergent Biosolutions position peaked at $3K in Q4 2013.
  • 168 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2014.

Based on Hoxton Financial's 13F filing for Q1 2014, filed 25 Apr 2014.